Kane A, Barza M, Baum J
Antimicrob Agents Chemother. 1981 Nov;20(5):595-9. doi: 10.1128/AAC.20.5.595.
Moxalactam was administered subconjunctivally in 100-mg doses to rabbits with infected eyes (Staphylococcus aureus endophthalmitis). High concentrations of drug were detected in the sclera, cornea, and choroid; much lower levels were found in the retina, whereas peak concentrations in the vitreous were about 6 microgram/ml. Repeated intramuscular injections of 50 mg/kg every 4 h produced peak serum levels of about 100 microgram/ml. A gradient between the choroid and the retina was again evident, and peak vitreous levels were about 6 microgram/ml after six injections. These data are consistent with the concept of a blood-retina barrier analogous to the blood-brain barrier. Moxalactam appears to penetrate the eye somewhat better than do other beta-lactams; however, the peak levels produced in the vitreous humor in this animal model were below the level required to inhibit most strains of Pseudomonas aeruginosa.
将莫西拉坦以100毫克剂量结膜下注射给患有感染性眼疾(金黄色葡萄球菌性眼内炎)的兔子。在巩膜、角膜和脉络膜中检测到高浓度的药物;在视网膜中发现的药物水平则低得多,而玻璃体内的峰值浓度约为6微克/毫升。每4小时重复肌肉注射50毫克/千克,血清峰值水平约为100微克/毫升。脉络膜和视网膜之间的梯度再次明显,六次注射后玻璃体内的峰值水平约为6微克/毫升。这些数据与类似于血脑屏障的血视网膜屏障概念一致。莫西拉坦似乎比其他β-内酰胺类药物对眼睛的穿透力稍强;然而,在这个动物模型中玻璃体液中产生的峰值水平低于抑制大多数铜绿假单胞菌菌株所需的水平。